Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

gyrA - DNA gyrase subunit A

Enterococcus faecalis V583

Petersen, A. et al., Grohs, P. et al., el Amin, N.A. et al., Wickman, P.A. et al.

Wickman, Black, Smith Moland, Thomson, Hanson,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of gyrA

High-level quinolone resistance in Enterococcus faecium was associated with mutations in both gyrA and parC genes in 10 of 11 resistant strains [1].

High impact information on gyrA

Against S. pneumoniae, garenoxacin behaved like moxifloxacin and sparfloxacin, being more affected by a single gyrA mutation than by a single parC mutation [2].
The quinolone resistance determining regions of gyrA and parC in four species of enterococci from environmental samples with reduced susceptibility to ciprofloxacin were sequenced [3].

Chemical compound and disease context of gyrA

A minimal inhibitory concentration of 8 microg ml(-1) to ciprofloxacin was not associated with any mutations in the gyrA and parC gene of Enterococcus casseliflavus and Enterococcus gallinarum [3].

Other interactions of gyrA

The quinolone resistance determining regions (QRDRs) of gyrA and parC in less-susceptible mutants were amplified by PCR and sequenced [4].

References

Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. el Amin, N.A., Jalal, S., Wretlind, B. Antimicrob. Agents Chemother. (1999) [Pubmed]
In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. Antimicrob. Agents Chemother. (2003) [Pubmed]
Analysis of gyrA and parC mutations in enterococci from environmental samples with reduced susceptibility to ciprofloxacin. Petersen, A., Jensen, L.B. FEMS Microbiol. Lett. (2004) [Pubmed]
In vitro development of resistance to DX-619 and other quinolones in enterococci. Wickman, P.A., Black, J.A., Smith Moland, E., Thomson, K.S., Hanson, N.D. J. Antimicrob. Chemother. (2006) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.